Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,919 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence of resistance-associated viral variants to the HIV-specific broadly neutralising antibody 10-1074 in a UK bNAb-naïve population.
Zacharopoulou P, Lee M, Oliveira T, Thornhill J, Robinson N, Brown H, Kinloch S, Goulder P, Fox J, Fidler S, Ansari MA, Frater J. Zacharopoulou P, et al. Among authors: brown h. Front Immunol. 2024 Mar 18;15:1352123. doi: 10.3389/fimmu.2024.1352123. eCollection 2024. Front Immunol. 2024. PMID: 38562938 Free PMC article.
Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy.
Martin GE, Sen DR, Pace M, Robinson N, Meyerowitz J, Adland E, Thornhill JP, Jones M, Ogbe A, Parolini L, Olejniczak N, Zacharopoulou P, Brown H, Willberg CB, Nwokolo N, Fox J, Fidler S, Haining WN, Frater J. Martin GE, et al. Among authors: brown h. Front Immunol. 2021 Jun 4;12:647688. doi: 10.3389/fimmu.2021.647688. eCollection 2021. Front Immunol. 2021. PMID: 34149690 Free PMC article. Clinical Trial.
Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption.
Pace M, Ogbe A, Hurst J, Robinson N, Meyerowitz J, Olejniczak N, Thornhill JP, Jones M, Waters A, Lwanga J, Kuldanek K, Hall R, Zacharopoulou P, Martin GE, Brown H, Nwokolo N, Peppa D, Fox J, Fidler S, Frater J. Pace M, et al. Among authors: brown h. Front Immunol. 2022 Aug 30;13:878743. doi: 10.3389/fimmu.2022.878743. eCollection 2022. Front Immunol. 2022. PMID: 36110857 Free PMC article.
CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA.
Martin GE, Pace M, Thornhill JP, Phetsouphanh C, Meyerowitz J, Gossez M, Brown H, Olejniczak N, Lwanga J, Ramjee G, Kaleebu P, Porter K, Willberg CB, Klenerman P, Nwokolo N, Fox J, Fidler S, Frater J. Martin GE, et al. Among authors: brown h. Front Immunol. 2018 May 4;9:928. doi: 10.3389/fimmu.2018.00928. eCollection 2018. Front Immunol. 2018. PMID: 29780387 Free PMC article.
CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype.
Thornhill JP, Pace M, Martin GE, Hoare J, Peake S, Herrera C, Phetsouphanh C, Meyerowitz J, Hopkins E, Brown H, Dunn P, Olejniczak N, Willberg C, Klenerman P, Goldin R, Fox J, Fidler S, Frater J; CHERUB investigators. Thornhill JP, et al. Among authors: brown h. Mucosal Immunol. 2019 Sep;12(5):1212-1219. doi: 10.1038/s41385-019-0180-2. Epub 2019 Jun 25. Mucosal Immunol. 2019. PMID: 31239514 Free article.
The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.
Lee MJ, Collins S, Babalis D, Johnson N, Falaschetti E, Prevost AT, Ashraf A, Jacob M, Cole T, Hurley L, Pace M, Ogbe A, Khan M, Zacharopoulou P, Brown H, Sutherland E, Box H, Fox J, Deeks S, Horowitz J, Nussenzweig MC, Caskey M, Frater J, Fidler S. Lee MJ, et al. Among authors: brown h. Trials. 2022 Apr 5;23(1):263. doi: 10.1186/s13063-022-06151-w. Trials. 2022. PMID: 35382844 Free PMC article.
HIV-1 DNA predicts disease progression and post-treatment virological control.
Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J; SPARTACTrial Investigators. Williams JP, et al. Among authors: brown h. Elife. 2014 Sep 12;3:e03821. doi: 10.7554/eLife.03821. Elife. 2014. PMID: 25217531 Free PMC article.
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption.
Hurst J, Hoffmann M, Pace M, Williams JP, Thornhill J, Hamlyn E, Meyerowitz J, Willberg C, Koelsch KK, Robinson N, Brown H, Fisher M, Kinloch S, Cooper DA, Schechter M, Tambussi G, Fidler S, Babiker A, Weber J, Kelleher AD, Phillips RE, Frater J. Hurst J, et al. Among authors: brown h. Nat Commun. 2015 Oct 9;6:8495. doi: 10.1038/ncomms9495. Nat Commun. 2015. PMID: 26449164 Free PMC article. Clinical Trial.
Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection.
Hoffmann M, Pantazis N, Martin GE, Hickling S, Hurst J, Meyerowitz J, Willberg CB, Robinson N, Brown H, Fisher M, Kinloch S, Babiker A, Weber J, Nwokolo N, Fox J, Fidler S, Phillips R, Frater J; SPARTAC and CHERUB Investigators. Hoffmann M, et al. Among authors: brown h. PLoS Pathog. 2016 Jul 14;12(7):e1005661. doi: 10.1371/journal.ppat.1005661. eCollection 2016 Jul. PLoS Pathog. 2016. PMID: 27415828 Free PMC article. Clinical Trial.
Levels of Human Immunodeficiency Virus DNA Are Determined Before ART Initiation and Linked to CD8 T-Cell Activation and Memory Expansion.
Martin GE, Pace M, Shearer FM, Zilber E, Hurst J, Meyerowitz J, Thornhill JP, Lwanga J, Brown H, Robinson N, Hopkins E, Olejniczak N, Nwokolo N, Fox J, Fidler S, Willberg CB, Frater J. Martin GE, et al. Among authors: brown h. J Infect Dis. 2020 Mar 16;221(7):1135-1145. doi: 10.1093/infdis/jiz563. J Infect Dis. 2020. PMID: 31776569 Free PMC article.
3,919 results